NASDAQ:TTOO - T2 Biosystems Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $6.63 -0.27 (-3.91 %) (As of 07/20/2018 04:00 PM ET)Previous Close$6.90Today's Range$6.60 - $6.9452-Week Range$2.53 - $9.98Volume480,705 shsAverage Volume530,621 shsMarket Capitalization$301.67 millionP/E RatioN/ADividend YieldN/ABeta1.26 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts. Receive TTOO News and Ratings via Email Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolNASDAQ:TTOO CUSIPN/A Webwww.t2biosystems.com Phone781-761-4646 Debt Debt-to-Equity Ratio-0.13 Current Ratio0.65 Quick Ratio0.61 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.66 million Price / Sales61.22 Cash FlowN/A Price / CashN/A Book Value$0.04 per share Price / Book165.75 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-62,420,000.00 Net Margins-1,003.23% Return on Equity-1,117.88% Return on Assets-105.28% Miscellaneous Employees161 Outstanding Shares43,030,000Market Cap$301.67 T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions What is T2 Biosystems' stock symbol? T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO." How were T2 Biosystems' earnings last quarter? T2 Biosystems Inc (NASDAQ:TTOO) released its quarterly earnings results on Tuesday, May, 8th. The medical equipment provider reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. The medical equipment provider had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.45 million. T2 Biosystems had a negative net margin of 1,003.23% and a negative return on equity of 1,117.88%. The firm's revenue was up 144.7% compared to the same quarter last year. View T2 Biosystems' Earnings History. What price target have analysts set for TTOO? 5 Wall Street analysts have issued 1-year target prices for T2 Biosystems' stock. Their forecasts range from $5.20 to $14.00. On average, they anticipate T2 Biosystems' stock price to reach $8.40 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price. View Analyst Ratings for T2 Biosystems. What is the consensus analysts' recommendation for T2 Biosystems? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about T2 Biosystems stock? Here are some recent quotes from research analysts about T2 Biosystems stock: 1. HC Wainwright analysts commented, "We note that T2Bacteria identifies five of the most common and deadly sepsis-causing species of bacteria, has 90% sensitivity and 98% specificity, and is the first FDA-cleared test to identify sepsis-causing bacteria directly from whole blood. Importantly, T2Bacteria provides test results in approximately five hours, which is more than 2.5 days faster than blood culture-dependent tests. This difference in time-to-result is clinically meaningful since rapid targeted treatment based on identification of causative pathogens is critical for clinical outcome, and every hour saved in time to implement a targeted therapy could decrease patient mortality by 8%, according to published literature." (5/30/2018) 2. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (5/9/2018) Are investors shorting T2 Biosystems? T2 Biosystems saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 2,638,785 shares, an increase of 41.6% from the May 31st total of 1,863,043 shares. Based on an average daily volume of 1,387,356 shares, the short-interest ratio is presently 1.9 days. Currently, 9.6% of the shares of the company are sold short. View T2 Biosystems' Current Options Chain. Who are some of T2 Biosystems' key competitors? Some companies that are related to T2 Biosystems include Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), Intersect ENT (XENT), OraSure Technologies (OSUR), AtriCure (ATRC), Tactile Systems Technology (TCMD), Cerus (CERS), K2M Group (KTWO), SurModics (SRDX), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK) and Neuronetics (STIM). Who are T2 Biosystems' key executives? T2 Biosystems' management team includes the folowing people: Mr. John P. McDonough, CEO, Pres & Director (Age 58)Prof. Michael J. Cima, Co-Founder & Director (Age 58)Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 39)Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory BoardMr. John M. Sprague, CFO & Sr. VP (Age 59) Has T2 Biosystems been receiving favorable news coverage? News headlines about TTOO stock have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. T2 Biosystems earned a daily sentiment score of 0.15 on Accern's scale. They also assigned headlines about the medical equipment provider an impact score of 45.46 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Who are T2 Biosystems' major shareholders? T2 Biosystems' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (1.58%), Fred Alger Management Inc. (0.24%) and Sit Investment Associates Inc. (0.17%). Company insiders that own T2 Biosystems stock include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro, Michael Terrence Gibbs and Stanley Lapidus. View Institutional Ownership Trends for T2 Biosystems. Which major investors are buying T2 Biosystems stock? TTOO stock was bought by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Sit Investment Associates Inc. and Essex Investment Management Co. LLC. Company insiders that have bought T2 Biosystems stock in the last two years include Darlene M Deptula-Hicks, David B Elsbree, Joanne Spadoro and Michael Terrence Gibbs. View Insider Buying and Selling for T2 Biosystems. How do I buy shares of T2 Biosystems? Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is T2 Biosystems' stock price today? One share of TTOO stock can currently be purchased for approximately $6.63. How big of a company is T2 Biosystems? T2 Biosystems has a market capitalization of $301.67 million and generates $4.66 million in revenue each year. T2 Biosystems employs 161 workers across the globe. How can I contact T2 Biosystems? T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected] MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 224 (Vote Outperform)Underperform Votes: 185 (Vote Underperform)Total Votes: 409MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?